Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer

Meng Qin1,2 · Junzo Hamanishi1 · Masayo Ukita1 · Koji Yamano1 · Shiro Takamatsu1 · Kaoru Abiko1,3 · Ryusuke Murakami1,4 · Taito Miyamoto1 · Haruka Suzuki1 · Akihiko Ueda1 · Yuko Hosoe1 · Akihito Horie1 · Ken Yamaguchi1 · Masaki Mandai1

Received: 2 June 2021 / Accepted: 12 October 2021 / Published online: 23 October 2021
© The Author(s) 2021

Abstract
Immunotherapy has experienced remarkable growth recently. Tertiary lymphoid structures (TLSs) and B cells may play a key role in the immune response and have a survival benefit in some solid tumors, but there have been no reports about their role in endometrial cancer (EC). We investigated the clinicopathological and pathobiological characteristics of the tumor microenvironment (TME) in EC. Patients with EC at Kyoto University Hospital during 2006–2011 were retrospectively included. In 104 patients with EC who met study inclusion criteria, 81 (77.9%) had TLSs, which consisted of areas rich in CD20+ B cells, CD8+ T cells, CD4+ T cells, and CD38+ plasma cells. The absence of TLS was independently associated with tumor progression (HR, 0.154; 95% CI, 0.044–0.536; P = 0.003). Patients with TLSs that included CD23+ germinal centers had better PFS. All tumor infiltrating lymphocytes were counted in the intratumor site. The number of CD20+ B cells was significantly larger in patients with TLSs than in those without TLS (P < 0.001). CD20+ B cells numbers were positively correlated with other TLSs. The larger number of CD20+ B cell was associated with better PFS (P = 0.015). TLSs and B cell infiltration into tumors are associated with favorable survival outcomes in patients with EC. They may represent an active immune reaction of the TME in endometrial cancer.

Keywords Tertiary lymphoid structures · B cells · Endometrial cancer · Survival outcomes · Immunohistochemistry · Immune response

Introduction
Endometrial cancer (EC) is one of the most common gynecologic malignancies in the world [1]. The most important risk factors for EC are all related to an unbalanced increase in circulating estrogen, such as irregular menstruation, obesity, and exposure to tamoxifen [2]. Atypical endometrial hyperplasia (AEH) prior to EC is a continuously changing disease process. AEH is a precancerous lesion of EC, so most patients with EC can be diagnosed at an early stage [3]. However, the prognosis of patients with advanced EC and poorly differentiated histology is relatively poor, which makes therapy challenging [4]. Primary surgery followed by chemotherapy or radiotherapy has been the long-standing standard treatment for patients with EC, with or without hormonotherapy.

Recently, immunotherapy and targeted therapy have become alternative adjuvant treatment options as genetic evaluation in EC has become more widespread [5, 6]. Immunotherapy has experienced a remarkable growth in the last few years, including the use of immune checkpoint inhibitors and research on adoptive cellular transfer [5]. With the use of anti-programmed death 1 (PD-1) and anti-programmed death ligand 1 (PD-L1) agents, significant breakthroughs have been made in targeted immunotherapy involving T
cells [7, 8]. Tumor cells interacting with immune cells in the tumor microenvironment (TME) mediate tumor formation, local invasion, and metastasis [9]. Tertiary lymphoid structures (TLSs), also called ectopic lymphoid tissues are B cell-rich structures in tumors that have recently been in the spotlight [10, 11]. There are many reports that TLSs exist in chronic inflammatory conditions, including autoimmune diseases, chronic infections, chronic graft rejection, and a variety of solid tumors [12]. TLSs serve as an effective site for tumor reactions in the human immune system and trigger an inflammatory response via infiltrating immune cells [13]. Recent studies have shown that proinflammatory cytokines and corticosteroid intake in the TME lead to TLSs [14]. The B cell pathway plays a key role in TLS formation and function [15]. The presence of TLSs has been demonstrated to be associated with beneficial survival outcomes in malignancies such as breast cancer [16, 17], lung cancer [18, 19], and colorectal cancer [20, 21]. However, there are no detailed reports about the relationships among TLS formation, local immune status, and clinical outcomes in patients with EC. Therefore, we aim to investigate the clinicopathological and pathobiological characteristics of the TME in EC, in order to explore whether TLSs are present in EC and affect survival outcomes. We used immunohistochemistry (IHC) to explore the relationship between TLSs and tumor infiltrating lymphocytes (TILs), especially B cells.

Materials and methods

Patients and samples

This retrospective study included patients with EC who underwent primary treatment (total hysterectomy and bilateral salpingo-oophorectomy with or without pelvic lymphadenectomy and para-aortic lymph node dissection) at Kyoto University Hospital during 2006–2011. Patients with any of the following characteristics were excluded: (1) incomplete surgery and residual tumor; (2) neoadjuvant chemotherapy or neoadjuvant radiotherapy; and (3) rare pathological types other than endometrioid adenocarcinoma, uterine serous carcinoma (USC), or mixed type (endometrioid and serous adenocarcinoma). All patients provided written informed consent. This study was approved by the ethics committee of Kyoto University Hospital.

The following data were extracted from electronic medical records from the Hospital Information King System: patient information, clinicopathological characteristics, adjuvant treatment, risk factors, and survival outcomes. Risk factors included tumor size, depth of myometrial invasion, lymphovascular space invasion (LVSI), parametrial involvement, lymph node metastasis, and microcystic, elongated, and fragmented (MELF) pattern. Progression-free survival (PFS) and overall survival (OS) were the most important results for this study. PFS was defined as the time interval between the date of the first diagnosis and the date of disease progression. OS was defined as the time interval between the date of the first diagnosis and the date of death [22]. In terms of histology, low-grade disease consisted of G1 or G2 endometrioid adenocarcinoma, and high-grade disease consisted of G3 endometrioid adenocarcinoma, USC, or mixed type.

We included 10 randomly selected patients with normal endometrium (including 5 cases in the proliferative stage and 5 cases in the secretory phase) and 10 patents with AEH as control groups in this study.

Immunohistochemistry

IHC was performed to detect CD8, CD20, CD4, CD38, and CD23 expression in patient samples using a standard protocol. The IHC conditions for each molecule in this study are shown in Table S1. Paraffin-embedded tumor blocks were cut into 4-µm-thick sections and then heated in a tissue-drying oven for 60 min at 60 °C. The tissue sections were deparaffinized in xylene in three steps of 15 min, 10 min, and 5 min, respectively. Next, the tissue sections were dehydrated with 99% (vol/vol) alcohol for 5 min, followed by 99% (vol/vol) ethanol for 2 min, 99% (vol/vol) ethanol for 2 min, and 70% (vol/vol) ethanol for 2 min and then rinsed with water. The antigen retrieval buffer consisted of 10 mM citrate buffer (pH 6.0) for all molecules. All sections were treated with methanol containing 3% (vol/vol) H2O2 for 15 min to block endogenous peroxidase activity, except for CD4, where methanol containing 0.3% (vol/vol) H2O2 was used. The sections were treated with normal mouse or rabbit serum (Histofine SAB-Po kit, #424,022 or 424,032, NICHIREI Biosciences Inc.) to block nonspecific binding of IgG. The sections were further incubated with corresponding primary antibody overnight at 4 °C. Next, the sections were stained with corresponding biotinylated secondary antibodies (NICHIREI Biosciences Inc.) for 30 min, followed by incubation with a streptavidin-peroxidase solution for 30 min. DAB (Sigma #D4418) was used to visualize peroxidase activity. Hematoxylin was used as a counterstain. Human tonsil tissue samples were used as positive controls for each molecule. Finally, the sections were dehydrated with alcohols in various percentages and xylene before coverslips were applied. All sections were washed in phosphate buffered saline (PBS), except for CD23, where PBS with 0.3% (vol/vol) Triton X-100 was used.

Evaluation of TLS and immunohistochemistry

A gynecological pathologist and two gynecological oncologists who have abundant experience in pathology independently examined the slides with hematoxylin–eosin (HE)
staining and IHC without any clinical information about the patient. A third reviewer was involved in a discussion to resolve differences. The presence, location, formation, and maturation of TLSs were assessed on each slide for all patients based on HE staining and IHC expression under the microscope. A TLS was defined as the area of ectopic lymphocyte aggregation larger than a microscopic field at 400x (0.03125 mm²). The TLS number was defined as the amount of TLS at 400× microscopic field in one slide.

Tumor infiltrating cells were divided into infiltrating lymphocytes in a tumor site and infiltrating lymphocytes in stroma within a tumor area according to their location. In this study, all TILs were counted in the intratumor site. We did not count immune cells in TLSs as TILs. CD8+ T cells, CD20+ B cells, and CD4+ T cells can be evaluated by the positive cell count method based on membrane proteins. For example, the evaluation steps for CD8+ T cells were: (1) distinguishing the intratumor area; (2) selecting and counting 10 fields with a large number of CD8+ T cells with a 400× magnification microscope; (3) selecting 5 fields with the most CD8+ T cell infiltration from the 10 fields in the previous step; and (4) taking the average value from these 5 fields as the number of CD8+ T cells on the slide. Finally, high and low expression of each molecule was divided by the mean value from the corresponding IHC evaluation results for each patient. To evaluate IHC results of CD38+ plasma cells (PCs), a semi-quantitative PC score was employed. In detail, the number of PCs was calculated by combining staining intensity and percent positive area. Staining intensity ranged from 0 to 3 (0, negative; 1, weak; 2, moderate; and 3, strong). The following scores were applied: score = 0, 0–5% of immune cells; score = 1, 6–20% of immune cells (moderate or strong intensity) or 6–100% of immune cells (weak intensity) (B); score = 2, 21–75% of immune cells (moderate or strong intensity); and score = 3, 76–100% of immune cells (moderate or strong intensity) (D) [23]. Low CD38+ PC density was defined as a PC score of 0 or 1. High CD38+ PC density was defined as a PC score of 2 or 3. Positive or negative expression of CD38 was determined if germinal centers (GCs) were present in TLSs.

Bioinformatics analysis

The expression profiles of RNA-sequencing data for EC were downloaded as Excel files from University of California–Santa Cruz (UCSC) Xena (https://xenabrowser.net/datapages/) in March 2020; they were based on raw data derived from the latest data from the Cancer Genome Atlas (TCGA). The mRNA gene data were transformed using the standard fragments per kilobase of transcript per million mapped reads standard method. The corresponding clinical information and survival data were also downloaded in the same way. High and low expression of each target gene was based on the median value of RNA-seq expression. The relationship between gene expression and PFS or OS was analyzed.

Statistical analysis

All statistical analyses were performed using SPSS (version 23.0; SPSS Inc., Chicago, IL, USA) and GraphPad Prism (version 7.0; GraphPad Software Inc., San Diego, USA). Student’s t test and the Mann–Whitney U test were used to compare continuous variables. Pearson’s chi-squared test and Fisher’s exact test were used to compare categorical variables. Continuous variables with normal distributions were presented as means ± standard deviation (SD). Non-normally distributed variables were presented as medians ± interquartile range (IQR) [24]. Survival analysis was performed with Kaplan–Meier curves, which were compared using the log-rank test. The association between each variable and survival was evaluated in a univariate Cox regression model. All variables with P < 0.05 and other meaningful variables based on the univariate analysis were included in a multivariate Cox proportional hazards regression model. Associations were evaluated based on hazard ratios (HRs) and 95% confidence intervals (CIs). Statistical significance was set at P < 0.05.

Results

Presence of TLS in EC and TLS classification

Figure S1 shows the flow diagram for patient selection. Ultimately, 104 patients with EC who met inclusion criteria were included in this study. We clearly observed some TLSs, as clusters of B cells, both inside tumors and in tumor stroma. Except for areas rich in CD20+ B cells, TLSs consisted of CD8+ T cells, CD4+ T cells, and CD38+ PCs, with or without GCs (Fig. 1). B cells were the most dominant TLS component.

TLS stage and location were evaluated. TLSs can be divided into two stages according to morphological structure and CD23 expression, as shown in Fig. 1: early stage, characterized by diffuse TLSs without CD23+ GCs and mature stage, characterized by aggregated TLSs with CD23+ GCs. TLS was also grouped into tumor infiltrative TLSs (iTLSs) and tumor border TLS (bTLSs) by location, as shown in Fig. 2. iTLSs were relatively rare, but bTLSs were nearly ubiquitous.

Comparison of TLSs and TILs in EC, normal endometrium, and AEH

No TLSs were observed in patients with normal endometrium. TLSs were observed in only two patients with
AEH. TLSs were more common in patients with EC than in patients with normal endometrium or AEH ($P < 0.001$) (Fig. 3), which indicated that TLS is a particular structure in tumor tissues. The number of CD8$^+$ T cells ($P < 0.001$), CD20$^+$ B cells ($P < 0.001$), CD4$^+$ T cells ($P < 0.001$), and the density of CD38$^+$ PCs ($P < 0.001$) were significantly higher in patients with EC than in patients with normal endometrium or AEH.

**Clinicopathological characteristics and prognostic value of TLS**

The 104 patients with EC were divided into two groups (Table 1) based on the analysis of slides: the TLS group ($N=81, 77.9\%$) and the no-TLS group ($N=23, 22.1\%). No significant differences were observed between groups in age ($P=0.469$), histology ($P=0.611$), International Federation of Gynecology and Obstetrics (FIGO) stage ($P=0.266$), adjuvant chemotherapy ($P=0.535$), and risk factors except positive ascites fluid cytology ($P=0.001$). Therefore, almost all the variables were similar in the survival analysis.

In univariate analysis, eight factors were associated with PFS, and two factors were associated with OS (Table 2). In multivariate analysis, high-grade histology was associated with inferior PFS (HR, $3.729; 95\%$ CI, $1.212–11.474; P=0.022$) and OS (HR, $5.121; 95\%$ CI, $1.092–24.010; P=0.038$). TLS absence was independently associated with PFS in patients with EC (HR, $0.154; 95\%$ CI, $0.044–0.536; P=0.003$), but not OS. Figure 4 shows the Kaplan–Meier curves for PFS (panel A) for all study patients. We evaluated...
Fig. 3 Comparison of TLS and TIL in EC, AEH, and normal endometrium. TLS highly existed in endometrial cancer than normal endometrium (N=10) and AEH (N=10) (A); The expression of CD8+T cells (B), CD20+ B cells (B), CD4+ T cells (B) and PCs (C) in EC patients were significantly higher than normal patients and AEH patients. (Abbreviations: TLS, tertiary lymphoid structures; EC, endometrial cancer; AEH, atypical endometrium hyperplasia; PC, plasma cell)

Table 1 The clinical and pathological characteristics between TLS and non-TLS group in overall included patients

| Characteristics                        | Total (N=104) | Non-TLS group (N=23) | TLS group (N=81) | P     |
|----------------------------------------|---------------|-----------------------|-------------------|-------|
| Age (Mean ± SD)                        |               |                       |                   | 0.469 |
| ≤50 year                               | 20 (19.2)     | 15 (65.2)             | 46 (56.8)         |       |
| >50 year                               | 84 (80.8)     | 8 (34.8)              | 35 (43.2)         |       |
| Histology                              |               |                       |                   | 0.611 |
| G1                                     | 36 (34.6)     | 11 (47.8)             | 25 (30.9)         |       |
| G2                                     | 15 (14.4)     | 3 (13.0)              | 12 (14.8)         |       |
| G3                                     | 27 (26.0)     | 5 (21.7)              | 22 (27.2)         |       |
| Serous                                 | 16 (15.4)     | 3 (13.0)              | 13 (16.0)         |       |
| Mixed type                             | 10 (9.6)      | 1 (4.3)               | 9 (11.1)          |       |
| FIGO stage                             |               |                       |                   | 0.266 |
| I                                      | 67 (64.4)     | 14 (60.9)             | 53 (65.4)         |       |
| II                                     | 8 (7.7)       | 1 (4.3)               | 7 (8.6)           |       |
| III                                    | 26 (25.0)     | 6 (26.1)              | 20 (24.7)         |       |
| IV                                     | 3 (2.9)       | 2 (8.7)               | 1 (1.2)           |       |
| Tumor size                             |               |                       |                   | 0.333 |
| ≤2 cm                                  | 21 (20.2)     | 3 (13.0)              | 18 (22.2)         |       |
| >2 cm                                  | 83 (79.8)     | 20 (87.0)             | 63 (77.8)         |       |
| Invasion depth                         |               |                       |                   | 0.329 |
| None or <1/2                           | 59 (56.7)     | 11 (47.8)             | 48 (59.3)         |       |
| ≥1/2                                   | 45 (43.3)     | 12 (52.2)             | 33 (40.7)         |       |
| Positive LVSI                         | 38 (36.5)     | 9 (39.1)              | 29 (35.8)         | 0.770 |
| Positive parametral involvement        | 18 (17.3)     | 4 (17.4)              | 14 (17.3)         | 0.990 |
| Positive lymph node metastasis         | 18 (17.3)     | 3 (13.0)              | 15 (18.5)         | 0.757 |
| Positive distant metastasis           | 15 (14.4)     | 6 (26.1)              | 9 (11.1)          | 0.071 |
| Positive ascites cytology              | 20 (19.2)     | 10 (43.5)             | 10 (12.3)         | 0.001*|
| Positive MELF pattern                  | 12 (11.5)     | 4 (17.4)              | 8 (9.9)           | 0.320 |
| Receiving pelvic/para-aortic lymphadenectomy | 88 (84.6) | 20 (90.0)             | 68 (84.0)         | 0.724 |
| Receiving adjuvant treatment           | 62 (59.6)     | 15 (65.2)             | 47 (58.0)         | 0.535 |
| Survival outcome                       |               |                       |                   |       |
| Recurrence                             | 20 (19.2)     | 10 (43.5)             | 10 (12.3)         |       |
| Death                                  | 13 (12.5)     | 3 (13.0)              | 10 (12.3)         |       |

Data are presented as number (%) or mean (± SD) or median (± IQR). (Abbreviations: TLS, Tertiary lymphoid structures; LVSI, lymphovascular space invasion; MELF, microcystic, enlarged and fragmented.*p < 0.05)
Table 2  The univariate and multivariate analysis of factors associated with PFS and OS in overall included patients

| Factors                  | N   | Univariate analysis | Multivariate analysis |
|-------------------------|-----|---------------------|-----------------------|
|                         |     | PFS                 | OS                    | PFS                  | OS                  |
|                         |     | HR 95%CI  P         | HR 95%CI  P           | HR 95%CI  P         | HR 95%CI  P         |
| Age                     |     |                    |                       |                     |                     |
| ≤ 50 year               | 20  | 0.466               | 0.956                 |                     |                     |
| > 50 year               | 84  | 1.579 0.462–5.391  | 1.503 0.333–6.792     |                     |                     |
| Histology               |     |                    |                       |                     |                     |
| High-grade              | 51  | 0.018* 0.037*       | 0.022* 0.038*         |                     |                     |
| Low-grade               | 53  |                     |                       |                     |                     |
| FIGO stage              |     |                    |                       |                     |                     |
| Early-stage             | 75  | 0.001*              | 0.092                 | 0.230               |                     |
| Late-stage              | 29  |                     |                       | 2.644 0.541–12.914  |                     |
| Adjuvant treatment      |     |                    |                       |                     |                     |
| No                      | 42  | 0.068               | 0.817                 |                     |                     |
| Yes                     | 62  | 2.773 0.926–8.299   | 0.874 0.279–2.732     |                     |                     |
| Tumor size              |     |                    |                       |                     |                     |
| ≤ 2 cm                  | 21  | 0.230               | 0.937                 |                     |                     |
| > 2 cm                  | 83  |                     |                       |                     |                     |
| Invasion depth          |     |                    |                       |                     |                     |
| None or < 1/2           | 59  | 0.001*              | 0.752                 | 0.578               |                     |
| ≥ 1/2                   | 45  |                     |                       |                     |                     |
| LVSJI                   |     |                    |                       |                     |                     |
| No                      | 66  | 0.004*              | 0.312                 | 0.742               |                     |
| Yes                     | 38  | 3.896 1.553–9.779   | 1.760 0.588–5.268     | 1.218 0.377–3.934  |                     |
| Parametrial involvement |     |                    |                       |                     |                     |
| No                      | 86  | 0.316               | 0.523                 |                     |                     |
| Yes                     | 18  | 1.678 0.610–4.620   | 1.524 0.418–5.554     |                     |                     |
| LN metastasis           |     |                    |                       |                     |                     |
| No                      | 86  | 0.002*              | 0.965                 | 0.218               |                     |
| Yes                     | 18  | 4.009 1.633–9.844   | 0.963 0.213–4.360     | 3.415 0.594–9.821  |                     |
| Distant metastasis      |     |                    |                       |                     |                     |
| No                      | 89  | <0.001*             | 0.030*                | 0.496               | 0.119               |
| Yes                     | 15  | 7.110 2.922–17.298  | 3.726 1.139–12.191    | 2.415 0.475–4.649  | 2.634 0.779–8.908  |
| Ascites                 |     |                    |                       |                     |                     |
| No                      | 84  | 0.005*              | 0.977                 | 0.960               |                     |
| Yes                     | 20  | 3.511 1.453–8.483   | 1.020 0.271–3.836     | 0.965 0.240–3.885  |                     |
the relationship between the presence of TLSs and survival outcomes by histology subgroup. In the low-grade histology ($P = 0.006$) (Fig. 4B) and high-grade histology ($P = 0.004$) (Fig. 4C) subgroups, patients with TLSs had better PFS than patients without TLSs. There were positive correlations between intratumoral CD20+ B cells and intratumoral CD8+ T cells, intratumoral CD4+ T cells, as well as plasma cells in patients with low-grade histology (Figure S2).

In addition, we compared the relationship between the TLS stage and survival outcomes in 81 TLS patients. There was no significant difference of PFS in overall TLS patients ($P = 0.206$, Fig. 4D) and low-grade histology subgroup ($P = 0.061$, Fig. 4E). However, the TLS patients with GCs had better PFS than those without GCs ($P = 0.039$, Fig. 4F) in high-grade histology. Moreover, by TLS location, there were four subtypes of patients. Figure 2 shows that patients with only iTLSs had the best PFS, followed by patients with both iTLSs and bTLSs. Patients without TLSs had the worst PFS ($P = 0.009$). There were no significant differences in OS by TLS location ($P = 0.822$). Similar results were obtained for PFS.

**Correlation between CD20+ B cells and TLS, as well as other TILs**

CD8+ T cells, CD20+ B cells, CD4+ T cells, and CD38+ PCs were common in endometrial tumors. The number of CD20+ B cells increased as the number of TLSs increased (Fig. 5A). The TLS group had significantly larger number of CD20+ B cells than the no-TLS group (Fig. 5B). The number of CD20+ B cells was positively correlated with CD8+ T cells ($P < 0.001$, $r = 0.415$), CD4+ T cells ($P = 0.014$, $r = 0.240$), and CD38+ PCs ($P < 0.001$, $r = 0.322$) (Fig. 5C, D, and E). Figure 6 and Table S2 show the relationships between intratumoral TILs and survival outcomes in all study patients and by histology subgroup. The larger number of CD20+ B cells ($P = 0.015$), CD8+ T cells ($P = 0.016$), and higher density of CD38+ PCs ($P = 0.012$) were associated with better PFS, while the smaller number of CD4+ T cells was associated with better OS ($P = 0.031$). Similar results were observed with data from the TCGA database. The larger number of CD20+ B cells ($P = 0.076$) and CD8+ T cells ($P = 0.006$), respectively, tended to be associated with better PFS (Fig. 6D and E).

**Discussion**

Recently, several immune checkpoint inhibitors are the focus of a new treatment strategy for treating different types of gynecologic malignancies [25–27]. TLSs, as clusters of immune cells, play a key role in the TME and is related to beneficial survival outcomes in several solid tumors. TLS
upregulation may lead to significant antitumor responses. Cabrita et al. indicated that TLSs play a key role in the immune microenvironment in melanoma, by conferring distinct T cell phenotypes [28]. Figenschau et al. reported that breast carcinomas frequently contain TLSs, and the presence of these structures is associated with aggressive tumors [29]. In HER2-positive and triple-negative breast cancer, the presence of TLSs is associated with superior survival [30]. Caro et al. found that TLSs cooperate with TILs in a coordinated antitumor immune response in patients with low-risk, early-stage colorectal cancer [31]. Dieu-Nosjean et al. first reported the presence of TLSs in non-small cell lung cancer (NSCLC); they named those structures tumor-induced bronchus-associated lymphoid tissue (Ti-BALT). Mature dendritic cell (DC-LAMP⁺) is a specific marker of Ti-BALT. And the number of DC is highly correlated with

---

**Fig. 4** The endometrial cancer patients with TLS were associated with beneficial survival outcomes. A The PFS of overall included patients characterized by the presence of TLS; the PFS of overall patients with low-grade histology (B) and high-grade histology (C) characterized by the presence of TLS; D the PFS of 81 TLS patients characterized by the presence of GC; the PFS of TLS patients with low-grade histology (E) and high-grade histology (F) characterized by the presence of GC. (Abbreviations: PFS, progression-free survival; OS, overall survival; TLS, tertiary lymphoid structures; GC, germinal center)

---

**Fig. 5** The number of CD20⁺B cells in TLS patients was increased and positively correlated with other TILs. A The number of intratumoral CD20⁺B cells was improved along with an increase in TLS number; B the number of intratumoral CD20⁺B cells in TLS patients was significantly higher than non-TLS patients; there were positive correlations in each of comparison between CD20⁺B cells and CD8⁺T cells (C), CD4⁺T cells (D), as well as PCs (E). (Abbreviations: TLS, tertiary lymphoid structures; PC, plasma cells)
the infiltration of CD4+ and T-bet+ Th1 cells in tumors, which is also related to survival outcomes [18]. Since there is a close relationship between TLSs and antitumor response in tumor samples, we naturally focused on TLS in EC. We found that the presence of TLSs in EC is associated with favorable survival outcomes.

Traditional secondary lymphoid organs (SLOs), including the spleen, lymph nodes, and tonsils, are important parts of the immune system [32]. TLSs have a similar structure as typical SLOs, with some slight differences. TLSs consist of B cell-rich regions, as well as T cells, PCs, follicular helper T (Tfh) cells, follicular dendritic cells (FDCs), and GCs [33]. There are also special lymph vessels characterized by high endothelial venules (HEVs) [34]. In chronic inflammatory conditions, such as autoimmune diseases, chronic infections, chronic graft rejection, and tumors, TLSs can serve as effective sites for tumor reactions in the TME and trigger an inflammatory response by infiltrating immune cells independently of SLOs [35].

TLS were divided into different stages according to CD23 expression. TLSs in the mature stage were associated with better survival outcomes. The presence of GCs within TLSs is correlated with exacerbated autoimmune response due to the generation of autoreactive B cells and HEVs. Other researchers have reported similar findings. Florian et al. divided TLSs into three subtypes based on the number of FDCs and mature B cells: (1) early TLSs, composed of diffuse, mixed B cells and T cells or dense lymphocyte clusters without FDCs and GC reactions; (2) primary follicular-like TLSs, which are dense lymphocyte clusters with FDCs but no GC reactions; and (3) secondary follicular-like TLSs, which are dense lymphocyte clusters with FDCs and active GC reactions [21]. Similarly, Silina et al. evaluated 138 patients with NSCLC and divided TLSs into three to four subtypes based on CD21 and CD23 expression [36]. They found that GC formation was impaired and TLS number had no prognostic value in patients treated with neoadjuvant chemotherapy. GCs gradually grow as TLSs develop, eventually becoming activated mature GCs.

Except the stage, TLSs can be classified by tumor location. In our study, patients with iTLSs had better survival outcomes than patients with bTLSs. Hiraoka et al. have also reported that there were two different localizations of pancreatic ductal carcinoma-associated TLSs, intratumoral and peritumoral. iTLS was associated better outcomes, independent of other survival factors. This finding can be explained by the antitumor microenvironment present in tumor tissues with intratumoral TLSs, which was suggested to be in an active state of cellular immune reaction and B cell reaction, as determined by the presence of TILs and tumor cytokines. These subtypes and classifications of TLSs can help us understand the relationships between the role of an immune reaction and antitumor ability in the TME.

Because TLS is an independent factor affecting survival, we further investigated how infiltrating immune cells around TLSs regulate the TME. We found a strong positive correlation between TLSs and intratumoral CD20+B cells. When we evaluated the role of CD20+B cells in survival, strikingly, high number of CD20+B cells was associated with favorable PFS. Thus, we hypothesize that B cells lead to a beneficial survival effect associated with TLSs. B cell-related pathways play a key role in...
the generation and formation of TLSs. At present, the B cell-related pathways associated with TLSs, known as the CCL19/CCL21/CCR7 axis or the CXCL13/CXCR5 axis, are attracting much attention [15]. The chemokine family related to B cells is necessary and sufficient for inducing TLS formation. It has been reported that the CCL19/CCL21/CCR7 axis functions in immune cells and helps cells migrate to SLOs or other tumor sites and activate the host cell response [37]. CCL19 or CCL21 produced by tumor cells is associated with tumor invasion and immune tolerance [38]. The CXCL13/CXCR5 axis is activated by the interaction of B cells and Tfh cells to accelerate the GC reaction; it participates in the migration of tumor B cells and Tfh cells in the TME [39]. In a recent report, TLSs-related gene signature (including CXCL13, CCL19) score was relatively higher in DNA polymerase epsilon (POLE) and microsatellite instability (MSI) subtypes than in other subtypes in TCGA data set of EC [40] And we could verify this result with another data set of endometrial cancer (n = 100, Clinical Proteomic Tumor Analysis Consortium [CPTAC]) [41] by the same method as the previous article [40] with single sample gene set enrichment analysis, and we also could get a same tendency of TLSs distribution in POLE and MSI subtypes (data not shown).

DCs, B cells, and Th17 cells are capable of producing these cytokines and are important for the special lymphoid tissue inducer cells during TLS formation [42]. Therefore, B cells and B cell-related pathways need to be further explored as new targets for immunotherapy. How to induce the formation of TLSs and how to inhibit tumorigenesis with TLSs via B cell-related pathways are future research directions.

**Conclusion**

In conclusion, TLSs exist in endometrial tumor tissue and are associated with favorable survival outcomes. TLS absence is an independent risk factor for disease progression in patients with EC. TLSs consist of areas rich in CD20+ B cells, CD8+ T cells, CD4+ T cells, and CD38+ PCs. TLSs can be divided into two stages according to the number of CD23+GCs, and the TLS patients with GCs had better PFS than those without GCs in high-grade histology. Patients with TLSs had significantly higher CD20+ B cell number than patients without TLSs. High CD20+ B cell number was associated with better PFS. TLSs play an important role in the human immune system in EC. TLSs and corresponding B cell pathways may become new anti-tumor targets after the T cell therapy revolution.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00262-021-03093-1.

**Acknowledgements** Junzo Hamanishi was supported by Grants-in-Aid for Scientific Research (18H02945). Besides, Dr. Meng Qin was supported by China Scholarship Council (201906210463).

**Authors’ contributions** M.Q. and J.H. contributed to study conception, study design, quality control of data, data analysis, interpretation, and manuscript preparation. T.M. and S.T. contributed to TCGA and CPTAC data analysis. M.U., K.A., R.M., A.U., H.S., A.K., K.Y., and M.M. contributed to sample collection, data acquisition, manuscript editing, and manuscript review.

**Data availability** All data sources described in this study are directed at the corresponding author.

**Declarations**

**Conflict of interest** The authors have no conflict of interest related to this study.

**Consent for publication** And all authors approved the final manuscript.

**Ethical approval** This study was approved by the ethics committee of Kyoto University Hospital.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Zhu G, Falahat R, Wang K, Mailloux A, Artzi N, Mule JJ (2017) Tumor-associated tertiary lymphoid structures: gene-expression profiling and their bioengineering. Front Immunol 8:767. https://doi.org/10.3389/fimmu.2017.00767
2. Tangjitgamol S, Anderson BO, See HT et al (2009) Management of endometrial cancer in Asia: consensus statement from the Asian oncology summit 2009. Lancet Oncol 10:1119–1127. https://doi.org/10.1016/S1470-2045(09)70290-6
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
4. Committee on Gynecologic Practice and Others (2015) The American college of obstetricians and gynecologists committee opinion no. 631: endometrial intraepithelial neoplasia. Obstet Gynecol 125:1272–8. https://doi.org/10.1097/01.aog.0000465189.50026.20
5. Di Tucci C, Capone C, Galati G, Iacobelli V, Schiavi MC, Di Donato V, Muzii L, Panici PB (2019) Immunotherapy in
endometrial cancer: new scenarios on the horizon. J Gynecol Oncol 30:e46. https://doi.org/10.3802/jgo.2019.30.e46

6. Gargiulo P, Dell Pepa C, Berardi S, Califano D, Scala S, Buonaguro L, Ciliberto G, Brauchi P, Pignata S (2016) Tumor genotype and immune microenvironment in POLE- ultramutated and MSI-hypermethylated endometrial cancers: new candidates for checkpoint blockade immunotherapy? Cancer Treat Rev 48:61–68. https://doi.org/10.1016/j.ctrv.2016.06.008

7. Hamanishi J, Mandai M, Iwashiki M et al (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci 104:3360–3365

8. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8:239–245

9. Weinstein AM, Storkus WJ (2015) Therapeutic lymphoid organogenesis in the tumor microenvironment. Adv Cancer Res 128:197–233. https://doi.org/10.1016/bs.acr.2015.04.003

10. Petitprez F, de Reynies A, Keung EZ et al (2020) B cells block immunotherapy. Cancer Treat Rev 48:61–68. https://doi.org/10.1016/j.ctrv.2016.06.008

11. Tokunaga R, Naseem M, Lo JH et al (2019) B cell and B cell-lymphoid structures in cancer tissues. Front Immunol 7:244. https://doi.org/10.3389/fimmu.2016.00401

12. Jones E, Gallimore A, Ager A (2018) Defining high endothelial venules and tertiary lymphoid structures in cancer. In: Clifton NJ (ed) Methods in molecular biology. Springer, New York, pp 99–118. https://doi.org/10.1007/978-1-4939-8709-2_7

13. Jones GW, Hill DG, Jones SA (2016) Understanding immune cells in tertiary lymphoid organ development: it is all starting to come together. Front Immunol 7:401. https://doi.org/10.3389/fimmu.2016.00401

14. Tang H,Qiu X, Timmerman C, Fu YX (2018) Targeting tertiary lymphoid structures for tumor immunotherapy. In: Clifton NJ (ed) Methods in molecular biology. Springer, New York, pp 275–286. https://doi.org/10.1007/978-1-4939-8709-2_16

15. Tokunaga R, Naseem M, Lo JH et al (2019) B cell and B cell-related pathways for novel cancer treatments. Cancer Treat Rev 73:10–19. https://doi.org/10.1016/j.ctrv.2018.12.001

16. Sofopoulos M, Fortis SP, Vaxevanis CK, Sotiriadou NN, Arno- giannaki N, Ardavanis A, Vlachodimitropoulos D, Perez SA, Cabrita R, Mauss M, Sanna A et al (2020) Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577:561–565. https://doi.org/10.1038/s41586-019-1914-8

17. Lee M, Heo SH, Song IH et al (2019) Presence of tertiary lymphoid structures in human breast cancer: a meta-analysis. Cancer Immunol Immunother CII 68:1733–1745. https://doi.org/10.1007/s00262-019-02407-8

18. Dieu-Nosjean MC, Antoine M, Danel C et al (2008) Long-term survival for patients with non-small cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26:4410–4417. https://doi.org/10.1200/JCO.2007.15.0284

19. de Chaisemartin L, Goc J, Damotte D et al (2011) Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res 71:6391–6399. https://doi.org/10.1158/0008-5472.can-11-0952

20. Schweiger T, Berghoff AS, Glogner C et al (2016) Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer. Clin Exp Metas 33:727–739. https://doi.org/10.1007/s10585-016-9813-y

21. Posch F, Silina K, Leibl S et al (2018) Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology 7:e1378844. https://doi.org/10.1080/2162402x.2017.1378844

22. Watanabe H, Okada M, Kaji Y et al (2009) New response evaluation criteria in solid tumours–revised RECIST guideline (version 1.1). Gan to Kagaku Ryoho. Cancer Chemother Pharmacol 36:2495–2501

23. Lohr M, Edlund K, Botling J et al (2013) The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Litt Cell Lett 333:222–228. https://doi.org/10.1038/landet.2013.0136

24. du Priel J-B, Rohrig B, Hommel G, Blettner M (2010) Choosing statistical tests: part 12 of a series on evaluation of scientific publications. Dtsch Arztebl Int 107:343–348. https://doi.org/10.3238/arztebl.2010.0343

25. Hamanishi J, Mandai M, Ikeda T et al (2015) Safety and antitumor activity of anti–PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33:4015–4022

26. Chung HC, Ros W, Delord J-P et al (2019) Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 37:1470–1478

27. Makker V, Raso DW, Vogelzang NJ et al (2018) Lenvatinib-pembrolizumab in patients with advanced endometrial cancer: updated results. Am Soc Clin Oncol 36(15Suppl):5596–5596

28. Cabrita R, Lauss M, Sanna A et al (2020) Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577:561–565. https://doi.org/10.1038/s41586-019-1914-8

29. Figsenschau SL, Fisman S, Fenton KA, Fenton C, Mortensen ES (2015) Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. BMC Cancer 15:101. https://doi.org/10.1186/s12885-015-1116-1

30. Kim A, Heo SH, Kim YA, Gong G, Jin Lee H (2016) An examination of the local cellular immune response to examples of both ductal carcinoma in situ (DCIS) of the breast and DCIS with micoinvasion, with emphasis on tertiary lymphoid structures and tumor infiltrating lymphocytes. Am J Pathol 146:137–144. https://doi.org/10.1039/ajcp/awq097

31. Di Caro G, Bergomas F, Gizzelli F et al (2014) Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res Off J Am Assoc Cancer Res 20:2147–2158. https://doi.org/10.1158/1078-0432.ccr-13-2590

32. Pitzalis C, Jones GW, Bombardieri M, Jones SA (2014) Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol 14:447–462. https://doi.org/10.1038/nri3700

33. Catherine Sautès-Fridman FP, Calderaro J, Fridman WH (2019) Tertiary lymphoid structures in the era of cancer immunotherapy. Nature 19:307–325. https://doi.org/10.1038/s41586-019-0144-6

34. Ager A, May MJ (2015) Understanding high endothelial venules: lessons for cancer immunology. Oncoimmunology 4:e1008791. https://doi.org/10.1080/2162402x.2015.1008791

35. Jing F, Choi EY (2016) Potential of cells and cytokines/chemokines to regulate tertiary lymphoid structures in human diseases. Immune Netw 16:477–480. https://doi.org/10.4110/in.2016.16.5.271

36. Silina K, Soltermann A, Attar FM et al (2018) Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res 78:1308–1320. https://doi.org/10.1158/0008-5472.can-17-1987

37. Pang MF, Georgoudaki AM, Lambri L et al (2016) TGF-beta1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/
CCL21-mediated chemotaxis. Oncogene 35:748–760. https://doi.org/10.1038/onc.2015.133

38. Pimenta EM, Barnes BJ (2014) Role of tertiary lymphoid structures (TLS) in anti-tumor immunity: potential tumor-induced cytokines/Chemokines that regulate TLS formation in epithelial-derived cancers. Cancers 6:969–997. https://doi.org/10.3390/cancers6020969

39. Workel HH, Lubbers JM, Arnold R et al (2019) A transcriptionally distinct CXCL13(+)CD103(+)CD8(+) T-cell population is associated with B-cell recruitment and neoantigen load in human cancer. Cancer Immunol Res 7:784–796. https://doi.org/10.1158/2326-6066.cir-18-0517

40. Lin Z, Huang L, Li S et al (2020) Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure. Sci Rep 9(10):21530. https://doi.org/10.1038/s41598-020-78560-3

41. Dou Y, Kawaler EA, Cui Zhou D et al (2020) Proteogenomic characterization of endometrial carcinoma. Cell 20(180):729-748.e26. https://doi.org/10.1016/j.cell.2020.01.026

42. Silina K, Rulle U, Kalnina Z, Line A (2014) Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue? Cancer Immunol Immunother CII 63:643–662. https://doi.org/10.1007/s00262-014-1544-9

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.